Publications by authors named "Jose M Arencibia"

Claim this Profile
T
Tetrahydropyrido[4,3-d]pyrimidines as a new active scaffold for human topoisomerase II inhibitors.
Nicoletta Brindani, Maria Antonietta La Serra, Jose Antonio Ortega, Jose M Arencibia, Michela Nigro

Sci Rep· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer.
Sohail Jahid, Jose A Ortega, Linh M Vuong, Isabella Maria Acquistapace, Stephanie J Hachey, Jose M Arencibia

Cell Rep· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer.
Sohail Jahid, Jose A Ortega, Linh M Vuong, Isabella Maria Acquistapace, Stephanie J Hachey, Jose M Arencibia

Cell Rep· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II α over β.
Jose Antonio Ortega, Jose M Arencibia, Elirosa Minniti, Jo Ann W Byl, Sebastian Franco-Ulloa

J Med Chem· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting topoisomerase II with trypthantrin derivatives: Discovery of 7-((2-(dimethylamino)ethyl)amino)indolo[2,1-b]quinazoline-6,12-dione as an antiproliferative agent and to treat cancer.
Elena Catanzaro, Nibal Betari, Jose M Arencibia, Serena Montanari, Claudia Sissi

Eur J Med Chem· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, Dynamic Docking, Biochemical Characterization, and Pharmacokinetics Studies of Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.
Jose M Arencibia, Nicoletta Brindani, Sebastian Franco-Ulloa, Michela Nigro, Jissy Akkarapattiakal Kuriappan

J Med Chem· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.
Jose Antonio Ortega, Laura Riccardi, Elirosa Minniti, Marco Borgogno, Jose M Arencibia

J Med Chem· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacophore Identification and Scaffold Exploration to Discover Novel, Potent, and Chemically Stable Inhibitors of Acid Ceramidase in Melanoma Cells.
Jose Antonio Ortega, Jose M Arencibia, Giuseppina La Sala, Marco Borgogno, Inga Bauer

J Med Chem· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lid domain plasticity and lipid flexibility modulate enzyme specificity in human monoacylglycerol lipase.
Laura Riccardi, Jose M Arencibia, Luca Bono, Andrea Armirotti, Stefania Girotto

Biochim Biophys Acta Mol Cell Biol Lipids· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Allosteric Inhibitor Scaffold Targeting the PIF-Pocket of Atypical Protein Kinase C Isoforms.
Jose M Arencibia, Wolfgang Fröhner, Magdalena Krupa, Daniel Pastor-Flores, Piotr Merker

ACS Chem Biol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.
Christian Schmithals, Verena Köberle, Hüdayi Korkusuz, Thomas Pleli, Bianca Kakoschky, Jose M Arencibia

Cancer Res· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular mechanism of regulation of the atypical protein kinase C by N-terminal domains and an allosteric small compound.
Hua Zhang, Sonja Neimanis, Laura A Lopez-Garcia, José M Arencibia, Sabine Amon

Chem Biol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AGC protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases.
José M Arencibia, Daniel Pastor-Flores, Angelika F Bauer, Jörg O Schulze, Ricardo M Biondi

Biochim Biophys Acta· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site.
Katrien Busschots, Laura A Lopez-Garcia, Carmen Lammi, Adriana Stroba, Stefan Zeuzem, Jose M Arencibia

Chem Biol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression profiling reveals overexpression of TSPAN13 in prostate cancer.
Jose M Arencibia, Susana Martín, Francisco J Pérez-Rodríguez, Ana Bonnin

Int J Oncol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doxazosin induces apoptosis in LNCaP prostate cancer cell line through DNA binding and DNA-dependent protein kinase down-regulation.
José M Arencibia, Mónica Del Rio, Ana Bonnin, Rita Lopes, Nicholas R Lemoine

Int J Oncol· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
Jose M Arencibia, Ana M Bajo, Andrew V Schally, Magdalena Krupa, Ioulia Chatzistamou

Anticancer Drugs· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis